BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 3,287,021 shares of Zenas BioPharma common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock, Inc. reported beneficial ownership of 3,287,021 shares of Zenas BioPharma common stock.
  • Percent of class: The reported holdings represent 5.0% of the outstanding common shares of Zenas BioPharma.
  • Sole voting power: BlackRock reported sole voting power over 3,226,537 shares.
  • Sole dispositive power: BlackRock reported sole dispositive power over 3,287,021 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power were reported as 0.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Filer type: BlackRock, Inc. is classified as a parent holding company or control person (type HC), incorporated in Delaware.

BlackRock's Schedule 13G Filing on Zenas BioPharma Common Stock

According to the Schedule 13G filed on October 27, 2026, BlackRock, Inc., headquartered at 50 Hudson Yards, New York, NY 10001, reported aggregate beneficial ownership of 3,287,021 shares of Zenas BioPharma common stock (CUSIP 98937L105). The filing states that this represents 5.0% of the outstanding shares of that class. BlackRock is identified as a parent holding company or control person under Rule 13d-1(b)(1)(ii)(G), and the filing was signed by Spencer Fleming, Managing Director, on behalf of BlackRock, Inc.

The filing notes, in accordance with SEC Release No. 34-39538 (January 12, 1998), that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and does not include securities beneficially owned by other business units whose ownership is disaggregated from the Reporting Business Units under that release. The identity and classification of the relevant subsidiaries are provided in Exhibit 99 attached to the filing.

Regarding the receipt of dividends or proceeds from sale, the filing disclosed that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of ZENAS BIOPHARMA," and further stated that "no one person's interest in the common stock of ZENAS BIOPHARMA is more than five percent of the total outstanding common shares." Zenas BioPharma's principal executive offices are listed at 852 Winter Street, Suite 250, Waltham, MA 02451.

What Was Disclosed

BlackRock, Inc. filed a Schedule 13G disclosing 3,287,021 shares, or 5.0%, of Zenas BioPharma common stock beneficially owned as of September 30, 2026, with sole voting power over 3,226,537 shares and sole dispositive power over all 3,287,021 shares.